Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

Cancer

Volumn 120, Issue 11, 2014, Pages 1617-1619

  Ascierto, Paolo A ^a   Margolin, Kim ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; IPILIMUMAB; VEMURAFENIB;

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; LYMPHOCYTIC INFILTRATION; MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK BENEFIT ANALYSIS; SURVIVAL TIME; TREATMENT INDICATION;

HUMANS; IMMUNOTHERAPY; MELANOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84901358299     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28622     Document Type: Editorial

References (17)

1. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008; 26: 527-534.
2. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367: 1694-1703.
3. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122-133.
4. Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013; 368: 1365-1366.
5. Ascierto PA, Simeone E, Giannarelli D, et al. Sequencing of BRAFinhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med. 2012; 10: 107.
6. Ascierto PA, Simeone E, Grimaldi AM, et al. Do BRAF inhibitors select for populations with different disease progression kinetics? J Transl Med. 2013; 11: 61
7. Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014; 120: 1695-1701.
8. European Commission-Community Register of Medicinal Products. Updated October 2013. Available at: http://ec.europa.eu/health/documents/community- register/html/h698.htm. Accessed November 2013.
9. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010; 11: 155-164.
10. Ascierto PA, Chiarion Sileni V, Del Vecchio M, et al. The European ipilimumab Expanded Access Programme (EAP): efficacy and safety data from the Italian cohort of patients with pretreated, advanced melanoma. Ann Oncol. 2012; 23 (suppl 9): ix367-ix375.
11. Weber JS, Dummer R, de Pril V, et al; MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013; 119: 1675-1682.
12. Ascierto PA, Simeone E, Chiarion-Sileni V, et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of ipilimumab expanded access programme (EAP). J Clin Oncol. 2013; 31 (suppl): abstract 9035.
13. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013; 19: 1225-1231.
14. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010; 70: 5213-5219.
15. Schilling B, Sucker A, Griewank K, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer. 2013; 133: 1653-1663.
16. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 23: 7412-7420.
17. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012; 13: 459-465.